suMMARY The effect of amiodarone on survival was assessed in patients with hypertrophic cardiomyopathy and ventricular tachycardia in a drug trial with historical controls. During 1976 and 1977, 24 hour (seven) 
The high risk of sudden death was one of the earliest recognised features and is the most important problem in the management of patients with hypertrophic cardiomyopathy. [1] [2] [3] [4] [5] [6] Approximately 25% of patients show bursts of ventricular tachycardia during electrocardiographic monitoring, and they are at even greater risk.7-" Amiodarone has been available in the United Kingdom since 1973, initially for use on compassionate grounds in specified patients with refractory arrhythmia. Once its efficacy was demonstrated'2 3 we have since 1978 extended its use to patients with hypertrophic cardiomyopathy and ventricular arrhythmia. 14 
Results
The mean and maximum rate and duration of ventricular tachycardia were similar in the two treatment groups; the incidence of associated ventricular and supraventricular arrhythmias was marginally higher in the amiodarone group (Table 1) . There were no significant differences in clinical, prognostic, echocardiographic, or haemodynamic features between the two groups (Tables 2 and 3) .
Of patients with ventricular tachycardia, five of 24 who were treated with conventional antiarrhythmic drugs died suddenly and unexpectedly within three years, whereas all 21 who received amiodarone survived three years or longer (Fig. 1) . Treatment with amiodarone was associated with improved survival (p<0-04). The overall mortality in patients who did not have ventricular tachycardia was similar during antiarrhythmic agent in these patients,'4 and a randomised prospective study in patients with hypertrophic cardiomyopathy and ventricular tachycardia was never feasible. To date no patient has died suddenly while taking amiodarone either in this comparative series of patients with ventricular tachycardia or in our larger series of patients with hypertrophic cardiomyopathy and other arrhythmias.'6 It would not now be possible for us to justify a randomised prospective study of amiodarone and conventional antiarrhythmic agents in patients with hypertrophic cardiomyopathy and ventricular tachycardia. ' The characteristics of these two consecutive patient populations with hypertrophic cardiomyopathy and ventricular tachycardia were comparable. Clinical and prognostic features, the extent and distribution of left ventricular hypertrophy, left heart filling pressures, and the proportion of patients with left ventricular gradients were similar in the two groups. The characteristics of the episodes of ventricular tachycardia were also similar in patients who received conventional antiarrhythmic drugs and those who received amiodarone, while the incidence of associated supraventricular and ventricular arrhythmias was not 
